Understanding your FibroScan Results

Similar documents
Diabetes Liver Screen

Having a FibroScan. Patient & Family Guide. You do not need any special preparation before having a FibroScan.

Patient Information Leaflet Non-Alcoholic Fatty Liver Disease (NAFLD) fatty-liver

LOGIQ S8 XDclear 2.0 Liver Procedures

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured

Non-Alcoholic Fatty Liver Disease

Patient Information Leaflet Having a Fibroscan

NHIVNA Pre-conference Study Day Current Issues in HIV, Hepatitis and other Blood-borne Viruses In collaboration with BASLNF

Non Alcohol Fatty Liver Disease (NAFLD) An information guide

Nash with cirrhosis icd 10

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH

Nonalcoholic Fatty Liver Disease (NAFLD)

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Pathogenesis and Management of Non-Alcoholic Fatty Liver Disease

Primary Biliary Cholangitis

Liver cirrhosis There s more of it out there than you think!

Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse

Hepatology for the Nonhepatologist

UMHS-PUHSC JOINT INSTITUTE

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

MR Elastography of Liver

Fatty liver disease stages

Elastography in the. technically difficult patient. EPIQ ultrasound system. Ultrasound

Liver elastography ultrasound cpt code

Patterns of abnormal LFTs and their differential diagnosis

At Least 1 in 5 Patients in Your Practice Have Fatty Liver

CHAPTER 1. Alcoholic Liver Disease

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

Managing abnormal LFTs in Primary care

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

NONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012

Alcohol-Related Liver Disease

POWERED BY. Innovation in liver disease management

DIAGNOSIS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES

Screening cardiac patients for advanced liver disease

Cirrhosis. An information guide

Cirrhosis. A Chronic Liver Problem

Liver Stiffness in Patients After the Fontan Procedure is Correlated with Age at Time of Surgery and Time since Surgery

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Liver Fat Quantification

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

understanding CIRRHOSIS of the liver A patient s guide from your doctor and

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer

Primary Biliary Cirrhosis

Active Surveillance for Prostate Cancer

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

Monitoring Hepatitis C

Elaine A. Leigh DNP, FNP-BC Mercy Health Hepatitis C Clinic Hackley Campus / Fax

Diseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

NASH: An Explanatory Guide for Patients and their Families

EVALUATION OF ABNORMAL LIVER TESTS

Follow-up of pediatric chronic liver disease

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

FACTS AN EDUCATIONAL SERIES BROUGHT TO YOU BY GILEAD SCIENCES

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

All You Wanted to Know About Hepatocellular Carcinoma

Making the best use of liver biopsy: clinical perspective. Steve Ryder Wolfson Digestive Diseases Centre University of Nottingham

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Fatty Liver Disease. Mark Thursz. Imperial College

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

NON-ALCOHOLIC FATTY LIVER DISEASE:

Transient elastography in chronic liver diseases of other etiologies

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Cirrhosis of the Liver

Lysosomal Acid Lipase Deficiency (LAL-D)

NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49

British Liver Transplant Group Pathology meeting September Leeds cases

Presented by Ron Parker August 2017

University of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba

La sindrome metabolica e il suo impatto dopo la guarigione nel paziente HIV/HCV

ADME in NAFLD: Genes and Big Jeans Increase the Risk of Adverse Drug Reactions. Drug-Induced Liver Injury

Personalised medicine with state-of-the-art MR image analysis

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.

Ask the Experts Patient Education Program. Understanding the Progression of Liver Disease: Fibrosis

IT 의료융합 1 차임상세미나 복부질환초음파 이재영

NAFLD and NASH: The Not-So-New Kids on the Block

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Paris Hepatology Conference PROGNOSIS OF NASH

Non-Alcoholic Fatty Liver Disease

Computer-Aided Quantitative Analysis of Liver using Ultrasound Images

National Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008

Clinical Trials & Endpoints in NASH Cirrhosis

FDA Introductory Remarks Stephanie O. Omokaro, MD

LIVER BIOPSY. The liver

Bio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019

Normal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT

Transcription:

PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your liver. It measures fibrosis (scarring) and steatosis (fatty change) in your liver. Fatty change is when fat builds up in your liver cells. FibroScan will help your healthcare provider learn more about your liver disease. It can be used alone or with other tests (such as blood tests, imaging scans, or biopsies) that also measure scarring or fatty change in your liver. Date: Your FibroScan Results FibroScan steatosis result (CAP score): decibels per meter (db/m) Steatosis grade: FibroScan fibrosis result: kilopascals () Fibrosis score: Understanding your FibroScan Results 1/5

Your healthcare provider will talk with you about your results during your appointment. If you have questions, call your doctor s office. You can reach them Monday through Friday from 9:00 AM to 5:00 PM at 212-639-7336. The rest of this resource explains your FibroScan results in more detail, including how your healthcare provider uses your results to determine your steatosis grade and fibrosis score. You can read the sections below if you d like to learn more. About Your CAP Score Your CAP score is a measurement of fatty change in your liver. Your healthcare provider will use your CAP score to find out your steatosis grade. The CAP score is measured in decibels per meter (db/m). It ranges from 100 to 400 db/m. The table below shows ranges of CAP scores and the matching steatosis grade and amount of fatty change. CAP Score Steatosis Grade Amount of Liver with Fatty Change 238 to 260 db/m S1 11 to 33% 260 to 290 db/m S2 34 to 66% Higher than 290 db/m S3 67% or more About Your Fibrosis Result Your fibrosis result is a measurement of the amount of scarring Understanding your FibroScan Results 2/5

in your liver. FibroScan measures scarring by measuring the stiffness of your liver. The fibrosis result is measured in kilopascals () It s normally between 2 and 6. The highest possible result is 75. Many people with liver disease(s) have a result that s than the normal range. Your healthcare provider will use your FibroScan fibrosis result and your medical history to determine your fibrosis score. Fibrosis score F0 to F1: No liver scarring or mild liver scarring Fibrosis score F2: Moderate liver scarring Fibrosis score F3: Severe liver scarring Fibrosis score F4: Advanced liver scarring (cirrhosis) Using your FibroScan fibrosis result to estimate your fibrosis score The table below shows liver diseases, ranges of fibrosis results, and the matching fibrosis score. The ranges of fibrosis results in the table are estimates. This means that your actual fibrosis score (the score that your healthcare provider tells you) may not match the fibrosis score in the table. If you have more than one liver disease, you may not be able to use the table. To use the table, find the liver disease that you have on the left side of the table. Read across the row from left to right until Understanding your FibroScan Results 3/5

you find the range that includes your fibrosis result. Then, look at the top of that column to see the fibrosis score. F0 to F1 F2 F3 F4 Hepatitis B Hepatitis C 8 to 9 8 to 11 8 to 9 9 to 14 18 or 14 or HIV/HCV 7 to 11 11 to 14 14 or Coinfection Cholestatic 7 to 9 9 to 17 17 or Non-alcoholic 7.5 to 10 10 to 14 14 or Fatty Liver (NAFLD or NASH) Alcohol 7 to 11 11 to 19 19 or Related Your fibrosis result may be over-estimated (your liver may have less scarring than what your fibrosis result says) if you have: Liver inflammation. This can be caused by a recent liver illness or drinking alcohol. Benign (not cancerous) or cancerous tumors in your liver. Understanding your FibroScan Results 4/5

Liver congestion (when your liver is too full of blood or other fluids). This is usually caused by heart failure. Your FibroScan results may also be less accurate if you have: A body mass index (BMI) than 30 (obesity) A build-up of fluid in your abdomen (ascites) Too little bile flowing out of your liver (biliary obstruction) Understanding your FibroScan Results 2018 Memorial Sloan Kettering Cancer Center - Generated on October 6, 2018 Understanding your FibroScan Results 5/5